Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — BioStock Life Science Summit 2025
13 slides from Expres2ion Biotech Holding Ab's conference presentation, Nov 13, 2025
Slide 1: The deadliest threat in women's health deserves a better defence
Bent U. Frandsen – CEO 13 November 2025 The deadliest threat in women’s health deserves a better defence Hosted by STO: EXPRS2 ExpreS2ion Biotech Holding AB Org. Nr. 559033 - 3729
Slide 2: Breast Cancer: The #1 Killer in Women's Health
Breast Cancer: The #1 Killer in Women’s Health Current drugs save lives but leave too many behind HER2 Expression • 2.3 million women diagnosed each year 1 – the most common cancer HER2 globally receptor HER2 receptors • 685,000 annual deaths 1 – the leading cause of cancer mortality in send signals
Slide 3: ES2B-C001 – a First-in-Class BC Vaccine
ES2B - C001 – a First - in- Class BC Vaccine Based on technology already having clinical PoC and Phase III validation (COVID - 19, >4,000 subjects) HER2 protein • VLP concept exists in approved vaccines ; (all 4 extra - cellular domains, i.e. HPV vaccine against cervical cancer and polyclonal effect
Slide 4: Preclinical Proof-of-Concept: Robust Immune Response & Tumour Control
Preclinical Proof - of- Concept: Robust Immune Response & Tumour Control • Broad immune response: Vaccine induced polyclonal antibodies vs. HER2 Tumour - free survival 3 • Tumour growth inhibition: Vaccine induced Suppressed tumour growth A further advantage of ES2B-C001 over monoclonal antibodies b
Slide 5: From First Signals to Pharma Deal
From First Signals to Pharma Deal Build - up of robust clinical study data to pave the way for a licensing value inflection point 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Phase I: First human data Phase II: Proof of concept in Breast Cancer Target launch Potential Phase II in Gast
Slide 6: Significant Market Opportunity
Significant Market Opportunity Blockbuster potential in a market with high unmet needs Patient distribution by region and cancer type 1 Global market size: The Breast cancer therapy 1.000.000 market is €27B globally with a projected 7% CAGR over the next 5 years 2 800.000 Proven commercial value of
Slide 7: Big Pharma Bets Billions on HER2 Therapies
Big Pharma Bets Billions on HER2 Therapies Multi- billion dollar M&A and licensing deals show strong demand for innovative HER2 treatments Key transactions Year Product - generic name Phase Seller Acquirer Up - front ($M) Milestones ($M) Royalties Geography Scorpion 2025 STX - 478 I/II Eli Lilly 2,5
Slide 8: Pipeline overview
Pipeline overview Multiple shots on goal across cancer and infectious diseases, powered by our ExpreS2 platform Target Pre - clinical DISEASE Project/Target ID Identification Pharmacology cGMP / Tox Phase I Phase II Phase III Collaboration Partner Platform 1 100% Breast Cancer ES2B - C001/HER2 - VLP
Slide 9: Extensive Vaccine Development and Oncology Experience
Extensive Vaccine Development and Oncology Experience Executive Management Fully capable of Bent U. Frandsen CEO 30 years life science management, executing to MSc, Copenhagen Business School business development and finance experience phase II POC Dr. Max Søgaard CSO 25 years research experience Ph
Slide 10: Cash Balance & Key Drivers (1Q24 – 3Q25)
Cash Balance & Key Drivers (1Q24 – 3Q25) SEK millions 100 TO 10 Warrants • Q3 2025 cash (mSEK): 36.9 Rights AdaptVac Issue 82 • Oct 2025 TO 11 gross proceeds 80 Dividend 76 Grant (mSEK): 11.8 Prepayment 69 TO 11 60 Warrants • Current runway: Q2 2026 60 58 49 • Target milestones: Phase Ia (Q2’26) & P
Slide 11: Summary (Why Invest)
Summary (Why Invest) • Large unmet medical need • Differentiated therapeutic approach • Strong preclinical proof - of- concept • Catalysts ahead from clinical progress • Significant market & revenue potential • Experienced team & partnerships • Financially prudent with cash for near - term milestone
Slide 12: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to u nde rwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of
Slide 13: Q&A
Q&A NASDAQ FN: EXPRS2 Innovative vaccines for a healthier world investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — BioStock Life Science Summit 2025 on 6ix